This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
News & Press: COVID-19

ABN note to Neurology Clinical Directors. URGENT: Social isolation for high risk neurology patients

23 March 2020  
Share |

Dear Clinical Directors
 
You will be aware that the government is developing plans to support 1.5 million 'high risk' patients who have been advised to enter self-isolation for 3 months or more. These patients will be offered guaranteed medication and there will be support for food deliveries etc. The precise plans are in development but no doubt will be well publicised in due course. 
 
The ABN has developed guidance on patients who should be considered to be at high risk. Broadly, this includes immunosuppressed patients, those with bulbar and respiratory muscle weakness and those with other factors, such as cardiac disease. The enclosed guidelines should help identify these patient groups.
 
Some patient groups, such as MS on DMTs or MND will be easier to identify than others. A Prednisolone dose of less than 20mg per day is not considered high risk. Actively managed patients in neurology clinics are more likely to be at risk than those seen infrequently or managed by GPs on shared care agreements unless there are additional factors present (see guidelines document). 
 
The purpose of this email is to ask that you direct your consultants to urgently identify the patients in the high risk category, using the ABN Guidelines. Please use their NHS numbers so that the data can be used nationally. A register of high risk patients in each service will greatly facilitate support of this group. 
 
The process for what to do with this data is under development. Whether the patient contact will be directly from NHSE or from neuroscience centres is under discussion. The resource implications with possible resulting delays are well known to the decision makers. At this stage however, identifying the patients is the top priority. 
 
Further information will be sent through as it becomes available. The specialist societies such as ABN have been asked to disseminate this request due to their close relationship with neuroscience centres. The leadership of the ABN with, and via the RCP is in close contact with the Chief Medical Officer's department, and great efforts are being made to be as effective as possible.
 
The Devolved Administrations are making their own arrangements but are in close contact with NHSE.
 
Kind Regards

Jon Sussman, Cath Mummery & Chris Kipps 
Honorary Secretary; Chair, Services Committee; Chair, Quality Committee

 

Contact Us

Association of British Neurologists
Ormond House
27 Boswell Street
London
WC1N 3JZ

Telephone: +44 (0)20 7405 4060
Email: info@abn.org.uk

Registered Charity No. 1077893
Company No. 3816842

Follow Us